Literature DB >> 8181490

Radical hysterectomy after pelvic irradiation in patients with high risk cervical cancer or uterine sarcoma: morbidity and outcome.

B J Monk1, S Solh, M T Johnson, F J Montz.   

Abstract

BACKGROUND: The optimal treatment of patients with "high risk" cancer involving the uterine cervix has not been defined. These patients include those with "bulky" or barrel shaped cervical tumors, individuals with adenocarcinomas or sarcomas, and those who respond poorly to radiation. As these patients are at high risk of failure if treated with radiation, it has been proposed that radical hysterectomy be performed in combination with radiation to improve local control of disease. We review our recent experience with this combined modality approach.
METHODS: We reviewed patients treated at UCLA Medical Center between 1982 and 1990. All patients had multiple risk factors for poor local control. Twenty patients underwent radical hysterectomy (12 (60%) class II, 5 (25%) class III, one (5%) class IV, 2 (10%) class V) after pelvic irradiation. Fifty percent had "bulky" (> 4 cm) Stage I cervical cancer, while 45% had Stage II and 5% Stage III. Fifty percent of the patients had an element of adenocarcinoma. Two patients (10%) had uterine sarcoma with cervical involvement. Thirty percent of the study group had a poor response to preoperative radiation.
RESULTS: Seventy percent of patients had nodal metastasis. Post-operative morbidity included infections (50%), urinary retention (10%), and ileus (5%). Long term morbidity included ureteral obstruction (30%), small bowel obstruction (20%), chronic gastrointestinal dysfunction (10%), chronic pelvic pain (10%), urinary fistula (10%), and vault necrosis (5%). Morbidity was less if patients only received preoperative brachy or teletherapy alone. Sixty-five percent of subjects are alive without disease with a mean follow up of 26 months.
CONCLUSION: Although limited by the number of patients, we conclude that radical hysterectomy after radiation is morbid but may be effective in treating patients with 1) large cervical tumors, 2) cervical cancer that responds poorly to radiation, 3) small recurrent cervical tumors, 4) patients unable to undergo brachytherapy for cervical cancer, and 5) uterine sarcomas involving the cervix.

Entities:  

Mesh:

Year:  1993        PMID: 8181490

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  6 in total

1.  Management of genital fistulas in patients with cervical cancer.

Authors:  C Emmert; U Köhler
Journal:  Arch Gynecol Obstet       Date:  1996       Impact factor: 2.344

2.  Pain and Psychological Outcomes After Rehabilitative Treatment for a Woman With Chronic Pelvic Pain With Stage III Cervical Cancer: A Case Report.

Authors:  Meryl J Alappattu
Journal:  J Womens Health Phys Therap       Date:  2013 Sep-Dec

3.  Radiation-sparing managements for cervical cancer: a developing countries perspective.

Authors:  Myrna Candelaria; Lucely Cetina; Alicia Garcia-Arias; Carlos Lopez-Graniel; Jaime de la Garza; Elizabeth Robles; Alfonso Duenas-Gonzalez
Journal:  World J Surg Oncol       Date:  2006-11-13       Impact factor: 2.754

4.  The role of surgery in locally advanced carcinoma of cervix after sub-optimal chemoradiation: Indian scenario.

Authors:  Rajshekar S Kundargi; B Guruprasad; Nikesh Hanumantappa; Praveen Shankar Rathod; Uma K Devi; U D Bafna
Journal:  South Asian J Cancer       Date:  2013-07

5.  Brachytherapy versus radical hysterectomy after external beam chemoradiation: a non-randomized matched comparison in IB2-IIB cervical cancer patients.

Authors:  Lucely Cetina; Alicia Garcia-Arias; Myrna Candelaria; David Cantú; Lesbia Rivera; Jaime Coronel; Blanca Bazan-Perkins; Vladimir Flores; Aaron Gonzalez; Alfonso Dueñas-González
Journal:  World J Surg Oncol       Date:  2009-02-16       Impact factor: 2.754

6.  The Effect of Extrafascial Hysterectomy After Completion of External Beam Radiotherapy for Treatment of Locally Advanced Stages (IIB-III) of Cervical Cancer.

Authors:  Zahra Sarraf; Bahareh Hamedi; Soodabeh Hooshmand; Ahmad Mosalaie; Minoo Robati; Mozhdeh Momtahan; Pouya Farhadi
Journal:  Iran Red Crescent Med J       Date:  2013-12-05       Impact factor: 0.611

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.